Analysis – Page 12 – Goldea Capital

Quantum Leap Energy Enters into Memorandum of Understanding with European Nuclear Technology Company for Advanced Nuclear Fuel Supply Collaboration

Written by Customer Service on May 11, 2026. Posted in Public Companies.

MOU establishes framework for collaboration with the goal to supply HALEU to European advanced reactor developer, beginning 2028 DALLAS, May 11, 2026 (GLOBE NEWSWIRE) — ASP Isotopes Inc. (NASDAQ: ASPI) (“ASPI”) today announced that Quantum Leap Energy LLC (“we,” “QLE” or the “Company”), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, has entered into a non-binding Memorandum of Understanding (MOU) with a European nuclear technology company specializing in advanced nuclear reactor development and other next-generation nuclear energy solutions. “Securing reliable HALEU supply is one of the most critical challenges facing the advanced nuclear industry today. This MOU is a meaningful step in QLE’s mission to build...

ROE Dental Laboratory Becomes First U.S. Lab to Deploy an Extensive Fleet of 3D Systems Jetted-Denture Printing Systems Across Multiple Sites

Written by Customer Service on May 11, 2026. Posted in Public Companies.

ROE triples its manufacturing capacity for high-precision, multi-material monolithic dentures, capitalizing on early success with the NextDent® 300 jetted-denture solution to meet accelerating U.S. demand. Expansion highlights rapid commercial adoption of 3D Systems’ industry-first multi-material Jetted Denture Solution. Reinforces 3D Systems’ leadership in digital dentistry as labs shift from conventional methods to scalable, high-margin digital workflows.ROCK HILL, S.C., May 11, 2026 (GLOBE NEWSWIRE) — 3D Systems (NYSE: DDD) today announced that ROE Dental Laboratory, one of the nation’s premier full-service dental labs, has purchased additional NextDent® 300 3D printers to expand its digital denture manufacturing capacity. With multiple systems in multiple locations now coming online, ROE becomes the leading dental laboratory...

Dyne Therapeutics Reports First Quarter 2026 Financial Results and Recent Business Highlights

Written by Customer Service on May 11, 2026. Posted in Public Companies.

– Positive pre-BLA meeting completed with FDA for z-rostudirsen in exon 51 DMD; on track for BLA submission in Q2 2026 and potential launch in Q1 2027 – – Positive cardiopulmonary results and long-term dystrophin data from Phase 1/2 DELIVER trial of z-rostudirsen in exon 51 DMD presented at MDA conference – – Completion of enrollment in registrational expansion cohort of Phase 1/2 ACHIEVE trial of z-basivarsen in DM1 on track for Q2 2026; global confirmatory Phase 3 HARMONIA trial initiated – – New preclinical data to be presented at ASGCT underscore differentiated capability of clinically validated FORCETM platform to cross the blood-brain barrier – WALTHAM, Mass., May 11, 2026 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering...

Alterity Therapeutics Announces Publication Demonstrating the Utility of Quantitative MRI as a Biomarker for Multiple System Atrophy

Written by Customer Service on May 11, 2026. Posted in Public Companies.

– Peer-reviewed study from the bioMUSE Natural History Study shows advanced MRI method detects disease-specific iron accumulation that supports diagnosis and correlates with clinical severity in patients with Multiple System Atrophy (MSA) – – Findings support QSM as an objective imaging biomarker to enable earlier diagnosis and assess iron-modulating therapies in MSA, including Alterity’s lead candidate ATH434 – MELBOURNE, Australia and SAN FRANCISCO, May 11, 2026 (GLOBE NEWSWIRE) — Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the publication of a peer-reviewed study in NeuroImage, a leading journal in human brain imaging, demonstrating that quantitative susceptibility mapping...

Labrador Gold Announces Option Agreement with Pacific Ridge to Acquire Mariposa and Eureka Dome Gold Projects in the Prolific White Gold District, Yukon

Written by Customer Service on May 11, 2026. Posted in Mergers And Acquisitions.

TORONTO, May 11, 2026 (GLOBE NEWSWIRE) — Labrador Gold Corp. (TSX.V: LAB | FNR: 2N6) (“LabGold” or the “Company”) is pleased to announce that it has signed an option agreement dated May 8, 2026 with Pacific Ridge Exploration Limited ((PEX: TSXV; PEXZF: OTCQB) (“Pacific Ridge”) to acquire a 100% interest in the Mariposa and Eureka Dome gold projects, Yukon Territory. Mariposa Project Highlights The 16,000 ha Mariposa project consists of 795 claims situated in the White Gold District, approximately 120 kilometres southeast of Dawson City and is accessible by fixed wing aircraft and winter road. The project lies approximately 15 kilometres east of the proposed Northern Access Route (NAR), an all-season road being constructed from Dawson City to the Coffee Gold project (figure 2). The property is 40 kilometres southeast of White Gold’s...

4basebio Launches Enzymatic ssDNA Platform

Written by Customer Service on May 11, 2026. Posted in Public Companies.

4basebio PLC (“4basebio” or the “Company”) 4basebio Launches Enzymatic ssDNA PlatformOvercomes critical manufacturing and performance bottlenecks associated with traditional chemical synthesis, providing faster and more reliable ssDNA manufacturing to aid commercial scale up 4basebio team to present at ASGCT Annual Meeting 2026 in Boston, MACAMBRIDGE, UK – 11 May 2026 – 4basebio PLC (AIM: 4BB), a specialist in synthetic DNA manufacturing and nucleic acids for next-generation therapeutics, announces the commercial launch of its high-capacity single-stranded DNA (ssDNA) product line to accelerate the development of safer, more precise genetic therapies by enabling targeted gene editing, advanced cell engineering, and innovative nucleic acid-based medicines. Built on a proprietary enzymatic manufacturing process,...

ARKO Petroleum Corp. Reports First Quarter 2026 Results

Written by Customer Service on May 11, 2026. Posted in Public Companies.

RICHMOND, Va., May 11, 2026 (GLOBE NEWSWIRE) — ARKO Petroleum Corp. (Nasdaq: APC) (“APC” or the “Company”), one of the largest wholesale fuel distributors in the United States, today announced financial results for the first quarter ended March 31, 2026. First Quarter 2026 Key Highlights (vs. Year-Ago Period) 1,2Net income for the quarter increased to $8.1 million compared to $4.5 million. Adjusted EBITDA for the quarter increased to $36.4 million compared to $30.9 million. Net cash provided by operating activities for the quarter was $6.6 million compared to $14.9 million. Discretionary Cash Flow for the quarter was $25.0 million compared to $17.1 million. Total debt, net was $184.5 million and Net Debt was $313.5 million, in each case, as of March 31, 2026.Other Key HighlightsThe Company completed its initial public offering...

Kaspi.kz 1Q 2026 Financial Results

Written by Customer Service on May 11, 2026. Posted in Earnings Releases And Operating Results.

ALMATY, Kazakhstan, May 11, 2026 (GLOBE NEWSWIRE) — Joint Stock Company Kaspi.kz (“Kaspi.kz”, “we”) (Nasdaq:KSPI) today published its unaudited consolidated IFRS financial results for the quarter ended 31 March 2026 (“1Q 2026”). Letter from Mikheil Lomtadze, Co-Founder and CEO of Kaspi.kz: We’ve started the year with strong e-Commerce growth, higher purchase frequency and improving monetization. e-Commerce GMV grew 41% year-over-year on a constant-currency and pro-forma basis and orders grew 43% on pro-forma basis. Consumers are buying more frequently — purchases per consumer increased 44% to 15 purchases per quarter. At the same time, Kaspi.kz remained highly profitable, with adjusted EBITDA growing 9%. Our Board recommended a dividend of KZT 850 per ADS, representing a 64% payout ratio, subject to shareholder approval. This reflects...

EchoStar Announces Financial Results for the Three Months Ended March 31, 2026

Written by Customer Service on May 11, 2026. Posted in Earnings Releases And Operating Results.

ENGLEWOOD, Colo., May 11, 2026 (GLOBE NEWSWIRE) — EchoStar Corporation (NASDAQ: SATS) reported first quarter 2026 total revenue of $3.67 billion, compared to $3.87 billion in 2025. Net loss attributable to EchoStar in the first quarter of 2026 totaled $146.89 million, compared to $202.67 million in the year-ago quarter. Diluted loss per share was $0.51 in the first quarter of 2026, compared to $0.71 in 2025. Pay-TVNet pay-TV subscribers decreased approximately 366,000 in the first quarter of 2026, compared to a decrease of approximately 381,000 in the year-ago quarter. The company closed the quarter with 6.63 million pay-TV subscribers, including 4.84 million DISH TV subscribers and 1.79 million Sling TV subscribers.Retail WirelessRetail wireless subscribers increased by approximately 16,000 in the first quarter of 2026,...

Liquidia Corporation Reports First Quarter 2026 Financial Results

Written by Customer Service on May 11, 2026. Posted in Earnings Releases And Operating Results.

YUTREPIA® (treprostinil) inhalation powder net product sales of approximately $130 million in the first quarter of 2026 More than 4,500 unique patient prescriptions and approximately 3,750 patients treated between launch in June 2025 and April 30, 2026 Recorded third consecutive quarter of profitability, with net income of approximately $53 million, adjusted EBITDA of $71 million and an increase in cash and cash equivalents by $32 million compared to the fourth quarter of 2025 Actively screening PH-ILD patients in Phase 4 Tyvaso® and Tyvaso DPI® transition study and pivotal Phase 3 Re-Spire study of L606MORRISVILLE, N.C., May 11, 2026 (GLOBE NEWSWIRE) — Liquidia Corporation (NASDAQ: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular...

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals